The Neurogenome study: Comprehensive molecular profiling to optimize treatment for Danish glioblastoma patients

Area of Science:

• Neuro-oncology
• Genomics
• Translational research

Background:

• Glioblastoma (GBM) is an aggressive brain cancer with limited treatment options and poor prognosis.
• Current treatment strategies, implemented in 2005, show minimal improvement in patient survival.
• A deeper understanding of GBM biology is crucial for developing more effective therapies.

Purpose of the Study:

• To improve knowledge and treatment of glioblastoma through systematically collected translational data.
• To establish a national, comprehensive, translational, and omic protocol for GBM research.
• To facilitate the selection of eligible patients for experimental treatments based on genomic alterations.

Main Methods:

• Whole exome sequencing of glioblastoma tumor tissue since 2016.
• Whole genome sequencing (WGS) initiated in 2020.
• Systematic data collection and analysis through the Neurogenome study, including paired tumor samples from relapse surgery.

Main Results:

• Sequenced over 400 glioblastoma (GBM) patients, with over 100 paired tumor samples from relapse surgeries.
• Initiated the Neurogenome study in June 2022, a national protocol for comprehensive translational and omic data collection.
• The protocol integrates basic science to applied clinical science, including clinical trials, enhancing patient data utility.

Conclusions:

• The Neurogenome protocol serves as a foundation for future research at the Danish Comprehensive Cancer Center-Brain Tumor Center.
• The study aims to guide patient selection for experimental treatments by identifying genomic alterations.
• The article will present the Neurogenome study design and highlight selected projects based on patient inclusion.